Epilepsy and Seizure Panel
Use
This test is designed for individuals who have relevant features of epilepsy or a clinical or suspected diagnosis of epilepsy. It is also applicable for individuals with a history of seizures without neurocognitive differences, dysmorphic features, or other medical complications, as well as those with epilepsy and comorbidities including neurocognitive differences, dysmorphic features, or other medical complications.
Special Instructions
New York approved. Exome or Genome Platform with the option for Exome-Wide CNV Analysis as an add-on.
Limitations
The performance characteristics of these tests have been validated by PreventionGenetics LLC following CAP and CLIA regulations. However, these tests have not been cleared or approved by the FDA. This limitation may affect the interpretation of variants, especially novel or rare variants where there are no established clinical guidelines.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided